- Global Pharma News & Resources

Nobelpharma Signs a License Agreement for ProBioGen’s Vaccine Manufacturing Platform AGE1.CR.pIX®

Nobelpharma Signs a License Agreement for ProBioGen’s Vaccine Manufacturing Platform AGE1.CR.pIX®

BERLIN, Germany, August 12, 2021 / B3C newswire / -- ProBioGen is pleased to announce that Nobelpharma has signed a license agreement for the use of the AGE1.CR.pIX vaccine production platform to develop their lead vaccine. The signing of the agreement is yet another milestone in a series of fruitful collaborations between Nobelpharma and ProBioGen, among them the successful development of a highly efficient manufacturing process for Nobelpharma's highly relevant viral vaccine.

The advantages of ProBioGen's proven cell-based production platform for industrial processes are evident: Designed as true suspension cell line, the AGE1.CR.pIX grows in chemically defined medium and is free of any adventitious agents. This allows cultivation in large bioreactors with reduced lead times and thus a more controlled production process in closed systems.

Dr. Gabriele Schneider, Chief Business Officer at ProBioGen commented: "Cell-based systems for vaccine production offer a cost-effective, efficient and flexible alternative to traditional vaccine production, e. g. on chicken eggs. With the AGE1.CR.pIX, we have created an exceptionally robust and scalable system, which is becoming increasingly important and we are pleased about the increased demand."


Link to the press release


About ProBioGen
ProBioGen is a specialist in the development and manufacturing of complex therapeutic proteins.
Combining both state-of-the-art protein and virus platforms, based on ProBioGen's CHO.RiGHT® and AGE1.CR® expression and manufacturing platforms, respectively, together with intelligent product-specific technologies, yield biologics with optimized properties.
Rapid and integrated cell line and process development, comprehensive analytical development and robust GMP manufacturing is performed by a highly skilled and experienced team. All services and technologies are embedded in a total quality management system to assure compliance with international ISO and GMP standards (EMA/FDA).
ProBioGen has been operational for more than 25 years. At two locations in Berlin, more than 200 employees contribute to the creation of new therapies in medicine and groundbreaking innovations worldwide through their creative and meticulous work.



Dr. Gabriele Schneider
Chief Business Officer 
+49 (0)30 3229 35 100    

ProBioGen Press Contact
Sarah Wandrey
Corporate Communications

Editor Details

Last Updated: 12-Aug-2021